Baidu
map

Cell:eRNA在调节基因表达中发挥着至关重要作用

2017-01-15 佚名 生物谷

在细胞中,DNA经转录产生RNA,而RNA为细胞表达蛋白提供遗传指令。基因组的大部分经转录产生RNA,但是仅有一小部分RNA确实是来自基因组的蛋白编码区域。 美国宾夕法尼亚大学佩雷尔曼医学院宾州表观遗传学研究所主任、细胞与发育生物学教授Shelley Berger博士说,“为什么非编码区域会发生转录?它们的功能是未知的。” Berger、她的实验室博士后研究员Daniel Bose博士


在细胞中,DNA经转录产生RNA,而RNA为细胞表达蛋白提供遗传指令。基因组的大部分经转录产生RNA,但是仅有一小部分RNA确实是来自基因组的蛋白编码区域。

美国宾夕法尼亚大学佩雷尔曼医学院宾州表观遗传学研究所主任、细胞与发育生物学教授Shelley Berger博士说,“为什么非编码区域会发生转录?它们的功能是未知的。”

Berger、她的实验室博士后研究员Daniel Bose博士研究了增强子对基因表达的调节。增强子是基因组的非编码区域,与基因组的蛋白编码区域相隔较远。增强子提高附近的蛋白编码基因的表达率,因此细胞产生更多的所需的蛋白分子。非编码RNA的一小部分是神秘的增强子RNA(enhancer RNA, eRNA)。它们是由增强子序列经转录而产生的。尽管它们在促进基因表达时起着重要的作用,但是它们如何实现这一点是完全未知的。

为了获得关于这些神秘的eRNA的新认识,研究人员证实作为一种激活增强子转录的酶,CBP直接结合到eRNA上。这种简单的行为通过调节乙酰化而控制着有机体中的基因表达模式。乙酰化是一种指导在细胞核中紧密包裹的DNA松弛下来促进转录的化学标记。相关研究结果发表在2017年1月12日那期Cell期刊上,论文标题为“RNA Binding to CBP Stimulates Histone Acetylation and Transcription”。

Bose说,“我们体内的细胞具有相同的基因和DNA序列,仅在这些基因如何表达上存在差异。增强子和eRNA在这个过程中发挥着至关重要的作用。我们的研究发现了eRNA产生这些不同的基因表达模式的一个令人兴奋的新方式。我们想知道eRNA是否直接与CBP结合,结果发现它们确实如此。”

利用生化检测方法,他们证实CBP结合到eRNA上的区域也能够调节着CBP加入乙酰化化学标记的能力。通过结合到CBP的这个区域,eRNA能够直接地激活CBP的乙酰化活性。

Berger说,“在癌症生物学世界,人们对增强子和eRNA越来越关注,这是因为存在缺陷的增强子能够导致太多的或太少的蛋白表达,或者能够导致蛋白编码区关闭或启动,或者能够导致蛋白在错误的时间表达。”鉴于近期对人肿瘤进行的DNA测序结果表明与癌症和其他疾病相关的多种突变发生于基因组的增强子区域而不是蛋白编码区域,因此更多地了解增强子和eRNA如何发挥功能将有助于肿瘤学家。

Berger说,“事实上,这是比较重要的,这是因为我们证实eRNA在整个基因组中和体内指导蛋白表达中发挥着关键性作用。我们在全基因组中鉴定出eRNA是结合到CBP上的最为常见的RNA类型,而且鉴定出通过这种相互作用,eRNA在调节CBP活性和基因表达中发挥着一种至关重要的作用。”

原始出处

Daniel A. Bose, Greg Donahue, Danny Reinberg, Ramin Shiekhattar, Roberto Bonasio, Shelley L. Berger.RNA Binding to CBP Stimulates Histone Acetylation and Transcription.Cell.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023472, encodeId=31b420234e26b, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 01 01:55:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959996, encodeId=0bdd195999668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 14 18:55:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008728, encodeId=8f7b2008e28a7, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jul 10 18:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869737, encodeId=7ec61869e3721, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 23 09:55:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348024, encodeId=345f1348024be, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jan 17 03:55:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023472, encodeId=31b420234e26b, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 01 01:55:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959996, encodeId=0bdd195999668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 14 18:55:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008728, encodeId=8f7b2008e28a7, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jul 10 18:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869737, encodeId=7ec61869e3721, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 23 09:55:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348024, encodeId=345f1348024be, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jan 17 03:55:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-05-14 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023472, encodeId=31b420234e26b, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 01 01:55:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959996, encodeId=0bdd195999668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 14 18:55:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008728, encodeId=8f7b2008e28a7, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jul 10 18:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869737, encodeId=7ec61869e3721, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 23 09:55:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348024, encodeId=345f1348024be, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jan 17 03:55:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
    2017-07-10 般若傻瓜
  4. [GetPortalCommentsPageByObjectIdResponse(id=2023472, encodeId=31b420234e26b, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 01 01:55:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959996, encodeId=0bdd195999668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 14 18:55:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008728, encodeId=8f7b2008e28a7, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jul 10 18:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869737, encodeId=7ec61869e3721, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 23 09:55:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348024, encodeId=345f1348024be, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jan 17 03:55:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2023472, encodeId=31b420234e26b, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 01 01:55:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959996, encodeId=0bdd195999668, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 14 18:55:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008728, encodeId=8f7b2008e28a7, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jul 10 18:55:00 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869737, encodeId=7ec61869e3721, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Nov 23 09:55:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348024, encodeId=345f1348024be, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jan 17 03:55:00 CST 2017, time=2017-01-17, status=1, ipAttribution=)]

相关资讯

两篇Cell聚焦利用MPRA方法高通量检测影响基因表达的DNA变异

来自美国哈佛大学-麻省理工学院布罗德研究所(简称布罗德研究所)、哈佛大学、达纳-法伯癌症研究所/波士顿儿童癌症与血液疾病中心等机构的研究人员通过解决当前人类遗传学面临的一项关键挑战,证实一种工具应当有助解决哪些遗传变异实际上让人们有风险患上心脏病、糖尿病和一系列其他疾病。这项研究采用一种被称作“大规模并行报告基因检测(massively parallel reporter assay, M

PLoS One: 房颤电复律后,SLC25A20和PDK4基因表达下降

背景:心房颤动(AF)患者恢复窦性心律治疗的长期成功率有限。基因表达谱可能为房颤的病理生理机制提供新的视野。目的:比较电复律(ECV)前后全血基因表达,了解AF的病理生理机制,识别生物标记物。方法:46例进行ECV的持续性房颤患者,复律前1-2小时,及复律成功后4至6周,收集全血标本。检测配对样品的微阵列和血浆生物标志物。结果:测试的13942个基因中,对SLC25A20和PDK4高表达与房颤相关

Nature:重大突破!史上详细人DNA转录前起始复合体结构出炉!

作为所有生命必不可少的一个过程,基因表达分两步:DNA转录为RNA,然后RNA翻译为蛋白。在一项新的研究中,来自美国佐治亚州立大学、加州大学伯克利分校和西北大学等多家机构的研究人员将低温电镜技术(Cryo-EM)和最新的计算建模方法结合在一起,史无前例地详细解析出近原子分辨率下的人转录前起始复合体(transcription pre-initiation complex, PIC)的分子结构。

Oncogene:肿瘤抑制蛋白可通过结合DNA和RNA来控制基因表达活性

图片来源:medicalxpress.com可以结合DNA或RNA的蛋白质通常被分为不同类别,但近日来自瑞典和法国的研究人员通过研究揭示了p53蛋白结合DNA和RNA的机制,以及其如何在转录和蛋白质合成水平下控制基因表达的分子机制,相关研究刊登于国际杂志Oncogene上。 p53肿瘤抑制蛋白非常出名,因为其有能力结合DNA并且在转录水平上来控制基因表达,研究者通常会在人类癌症中频繁发现特殊的突

Nat Methods:在不同物种中比较不同Cas9蛋白激活物的基因激活潜力

CRISPR/Cas9系统是一种典型的允许科学家们对很多有机体和细胞类型的DNA序列进行编辑的工具。然而,科学家们也越来越认识到它能够被用来激活基因表达。为了这个目的,科学家们构建出众多人工合成的基因激活性Cas9蛋白(编者注:能够激活靶基因的Cas9蛋白,也译作Cas9蛋白激活物)来研究基因功能,或者在潜在的治疗方法中补偿不充足的基因表达。 美国哈佛大学维斯生物启发工程研究所(Wy

Nature:史上详细转录因子TFIID三维结构出炉,力助揭示人类基因表达秘密

你的DNA不只是控制你眼睛的颜色和你是否卷舌。你的基因含有制造你身体所有蛋白的指令,而这些指令是你的细胞让你存活所持续需要的。但是在此之前,基因表达在分子水平上如何运行的一些关键细节一直有点神秘。在一项新的研究中,来自美国加州大学伯克利分校、劳伦斯伯克利国家实验室和西班牙国家研究委员会(CSIC)罗卡索拉诺物理化学研究所的研究人员

Baidu
map
Baidu
map
Baidu
map